Adcetris Market Size, Trends, Share, Growth, and Opportunity Forecast, 2024 - 2031 Global Industry Analysis By Form (Liquid, and Powder), By Indication (Hodgkin lymphoma, Anaplastic large cell lymphoma (ALCL), and Others), By End-user (Hospitals, Oncology Clinics, Research Institutions, Drug Store, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and By Geography (North America, Europe, Asia Pacific, South America, and Middle East & Africa)

Adcetris Market Size and Forecast 2024 to 2031

The Global Adcetris Market was valued at USD 1,732.4 Million in 2023 and is anticipated to reach a value of USD 2,860.2 Million by 2031 expanding at a CAGR of 6.5% between 2024 and 2031.

To learn more about this report, request a free sample copy

Adcetris (Brentuximab vedotin) is a targeted cancer therapy drug, used for the treatment of certain types of Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL). It is an antibody-drug conjugate (ADC) used when the cancer cells have a protein called CD30, a protein found on cancer cells. This drug works by combining a monoclonal antibody with a chemotherapy drug to reduce the impact on healthy cells and target cancer cells. Adcetris are effective in relapsed patients, and has fewer side effects compared to traditional chemotherapy. Adcetris is a cancer medicine and has revolutionized treatment for CD30-positive lymphomas, offering a targeted approach and improved outcomes for patients. The market is influenced by factors such as rising incidences of lymphoma, increasing awareness and adoption, increasing research and development activities, and growing oncology market. Major trends shaping industry growth is developing medicines tailored to individual patient profiles.

Adcetris Market Major Driving Forces

·         Rising Incidences of Lymphoma: The increasing incidences of Lymphoma, especially in developed regions is a major market driver for Adcetris. Adcetris have demonstrated promising outcomes in treating Hodgkin lymphoma and anaplastic large cell lymphoma, which is significantly driving the market demand.

·         Increasing Awareness and Adoption: The increasing awareness lymphoma cancers and available medications is driving the Adcetris market growth. An increased awareness of Adcetris among healthcare professionals and patients is driving their adoption.

·         Increasing Research and Development Activities: The growing focus on research and development to explore new indications and combination therapies drives market growth. Moreover, researchers are focused on expanding the applications of Adcetris, which further fuels the market growth.

·         Growing Oncology Market: The rapidly growing oncology market is boosting demand for effective medications including Adcetris. The growth of oncology market driven by increased cancer cases, better diagnosis, treatment, and prevention of cancer, positively impacts the adoption of drugs such as Adcetris.

Adcetris Market Key Opportunities

·         Technological Advancements: The growing investments in research and development and clinical trials have led to the development of advanced techniques for the production and conjugation of adcetris. Ongoing innovation have improved efficacy and safety, making it a preferred option for many patients and healthcare professionals.

·         Combination Therapies: One of the major opportunity exist in increasing focus on combination therapies. There is an increasing evidence that combining adcetris with other treatments, such as targeted therapy, checkpoint inhibitors, and other immunotherapies to improve their effectiveness and enhancing therapeutic outcomes. 

·         Personalized and Targeted Therapies: The growing emphasis on developing medicines tailored to individual patient profile is creating significant opportunities for market expansion. The growing shifts towards more personalized and targeted therapies, ADCs such as Adcetris, which precisely target cancer cells, are gaining attention.

Adcetris Market Key Trends

·         Ongoing clinical trials and research into ADCs to explore new therapeutic uses for Adcetris beyond Hodgkin lymphoma and anaplastic large cell lymphoma

·         Growing shifts towards more personalized and targeted therapies which precisely target cancer cells are gaining traction

·         The development of biosimilars which could make the treatment more affordable and accessible in various regions

·         Ongoing advancement in technology have led to a new generation of ADCs with balanced stability and highly potent cytotoxic agents

·         An increased demand for low-toxicity & effective drugs is a major factor influencing demand for adcetris

·         The development of advanced techniques for the production and conjugation of ADCs has improved product quality

·         Increased adoption of antibody-drug conjugates, which combine the targeting ability of antibodies with the potency of chemotherapy drugs

Region-wise Market Insights

North America accounted for the largest market share at 38.7% in 2023 whereas, Asia Pacific is expected to register the fastest growth, expanding at a CAGR of 7.1% between 2024 and 2031.

To learn more about this report, request a free sample copy

In North America, the demand is driven by a high prevalence of Hodgkin lymphoma, favorable reimbursement policies, significant R&D expenditure, advanced healthcare infrastructure, and presence of key players operating in this region. Morover, a strong focus on development of innovative therapies, demand for antibody-drug conjugates, and rising healthcare expenses also contributes to the regional market growth. Europe holds the second-largest market for adcetris due to the increasing prevalence of cancer in European nations, advancements in cancer treatment, and increasing healthcare spending. In Asia-Pacific, the market is characterized by rising healthcare spending, growing awareness of cancer treatment, rising incidence of cancer, and improvements in healthcare which has created an increasing demand for adcetris. The Middle East and Africa has been witnessing a growing demand for adcetris due to growing healthcare investments​ whereas, in South America, the market is influenced by economic factors, with increasing prevalence of lymphoma, coupled with expanding healthcare.

Market Competition Landscape

The global adcetris market is characterized by high degree of competition among a large number of manufacturers. Key players in the adcetris market engage in strategies aimed at gaining a competitive edge. These strategies include product innovation, design differentiation, and the investments in research and development to meet evolving consumer preferences. Established brands leverage their reputation for quality and reliability to maintain market share, while newer entrants focus on disruptive innovations and unique selling propositions.

Major players in the market are aiming at entering into collaboration, mergers, acquisitions, partnerships, and agreements with other companies to develop new products for expanding their product portfolio.

Key players in the global adcetris market implement various organic and inorganic strategies to strengthen and improve their market positioning. Prominent players in the market include:

·         F. Hoffmann-La Roche AG

·         AstraZeneca plc

·         Seagen Inc.

·         AbbVie Inc.

·         ADC Therapeutics

·         GSK plc

·         Pfizer Inc.

·         Astellas Pharma Inc.

·         Merck & Co., Inc.

·         Sanofi S.A.

·         Bristol-Myers Squibb Company

·         Gilead Sciences, Inc.

·         Daiichi Sankyo Company Ltd.

·         Astellas Pharma, Inc.